MA35508B1 - Inhibiteurs pyrimidines de pde10 - Google Patents
Inhibiteurs pyrimidines de pde10Info
- Publication number
- MA35508B1 MA35508B1 MA6829A MA36829A MA35508B1 MA 35508 B1 MA35508 B1 MA 35508B1 MA 6829 A MA6829 A MA 6829A MA 36829 A MA36829 A MA 36829A MA 35508 B1 MA35508 B1 MA 35508B1
- Authority
- MA
- Morocco
- Prior art keywords
- pde10
- treatment
- relates
- present
- compounds
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 210000004227 basal ganglia Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des composés pyrimidines qui sont utiles en tant qu'agents thérapeutiques pour le traitement de troubles du système nerveux central associés à la phosphodiestérase 10 (pde10). La présente invention concerne également l'utilisation de tels composés pour le traitement de troubles neurologiques et psychiatriques, tels que la schizophrénie, la psychose ou la maladie de huntington, et ceux associés à une hypofonction striatale ou d'un dysfonctionnement des noyaux gris centraux.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527392P | 2011-08-25 | 2011-08-25 | |
| PCT/US2012/051522 WO2013028590A1 (fr) | 2011-08-25 | 2012-08-20 | Inhibiteurs pyrimidines de pde10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35508B1 true MA35508B1 (fr) | 2014-10-02 |
Family
ID=47746797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA6829A MA35508B1 (fr) | 2011-08-25 | 2014-03-13 | Inhibiteurs pyrimidines de pde10 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9062059B2 (fr) |
| EP (1) | EP2748151B1 (fr) |
| JP (1) | JP5648147B2 (fr) |
| KR (1) | KR101655635B1 (fr) |
| CN (1) | CN103917528B (fr) |
| AR (1) | AR087628A1 (fr) |
| AU (1) | AU2012299080B2 (fr) |
| BR (1) | BR112014004310B8 (fr) |
| CA (1) | CA2845578C (fr) |
| CL (1) | CL2014000450A1 (fr) |
| CO (1) | CO6890101A2 (fr) |
| CR (1) | CR20140085A (fr) |
| CY (1) | CY1117622T1 (fr) |
| DK (1) | DK2748151T3 (fr) |
| DO (1) | DOP2014000039A (fr) |
| EA (1) | EA023685B1 (fr) |
| ES (1) | ES2572527T3 (fr) |
| HR (1) | HRP20160635T1 (fr) |
| HU (1) | HUE028451T2 (fr) |
| IL (1) | IL230997A (fr) |
| MA (1) | MA35508B1 (fr) |
| ME (1) | ME02419B (fr) |
| MX (1) | MX357241B (fr) |
| MY (1) | MY157301A (fr) |
| NI (1) | NI201400014A (fr) |
| PE (1) | PE20141535A1 (fr) |
| PH (1) | PH12014500424A1 (fr) |
| PL (1) | PL2748151T3 (fr) |
| RS (1) | RS54788B1 (fr) |
| SG (1) | SG2014013536A (fr) |
| SI (1) | SI2748151T1 (fr) |
| TN (1) | TN2014000070A1 (fr) |
| TW (1) | TWI450895B (fr) |
| UA (1) | UA109735C2 (fr) |
| WO (1) | WO2013028590A1 (fr) |
| ZA (1) | ZA201401272B (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013052526A1 (fr) | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | Inhibiteurs triazolyles de pde10 |
| AU2012318874A1 (en) | 2011-10-06 | 2014-05-15 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine PDE10 inhibitors |
| US9284302B2 (en) | 2012-11-15 | 2016-03-15 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles as PDE 10 inhibitors |
| TW201422610A (zh) | 2012-11-15 | 2014-06-16 | Merck Sharp & Dohme | 作爲ｐｄｅ１０抑制劑之經二級醇取代之三唑 |
| EP2919783B1 (fr) * | 2012-11-15 | 2018-01-31 | Merck Sharp & Dohme Corp. | Cyclopropylimidazopyridine utilisable en tant qu'inhibiteur de pde10 |
| WO2014081617A1 (fr) | 2012-11-20 | 2014-05-30 | Merck Sharp & Dohme Corp. | Dérivés de pyridone substitués utilisés en tant qu'inhibiteurs de pde10 |
| EP2922823B1 (fr) * | 2012-11-20 | 2018-10-31 | Merck Sharp & Dohme Corp. | Inhibiteurs pyrimidines de pde10 |
| WO2014139150A1 (fr) * | 2013-03-15 | 2014-09-18 | Merck Sharp & Dohme Corp. | Dérivés de pyridizinone substitués utilisés en tant qu'inhibiteurs de la pde10 |
| MX373444B (es) | 2014-03-24 | 2020-04-30 | Novartis Ag | Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas. |
| JP7008704B2 (ja) * | 2016-11-28 | 2022-01-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| JP7478672B2 (ja) | 2018-06-27 | 2024-05-07 | エフ． ホフマン－ラ ロシュ アーゲー | カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物 |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| CA3096777A1 (fr) | 2018-06-27 | 2020-02-02 | F. Hoffmann-La Roche Ag | Nouveaux composes de pyridine et de pyrazine en tant qu'inhibiteurs du recepteur cannabinoide 2 |
| US12544364B2 (en) | 2020-06-05 | 2026-02-10 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
| CN116137811B (zh) * | 2020-06-05 | 2026-01-09 | 诺埃玛制药公司 | 用于治疗杜尔雷斯综合征的磷酸二酯酶10抑制剂的用途 |
| IL305923A (en) * | 2021-03-17 | 2023-11-01 | Merck Sharp & Dohme Llc | Prodrugs for PDE10 compounds |
| EP4490148A4 (fr) * | 2022-03-11 | 2026-03-18 | Merck Sharp & Dohme Llc | Analogues de pyrimidine cycliques non aromatiques utilisés en tant qu'inhibiteurs de glucosylcéramide synthase |
| WO2023192170A1 (fr) * | 2022-04-01 | 2023-10-05 | Merck Sharp & Dohme Llc | Procédé de préparation de ((1s,2s)-2-(5-méthylpyridin-2-yl)cyclopropyl)méthanol |
| WO2023184486A1 (fr) * | 2022-04-01 | 2023-10-05 | Merck Sharp & Dohme Llc | Procédé de préparation de ((1s, 2s)-2-(5-méthylpyridin-2-yl)cyclopropyl)-méthanol |
| CN115403527B (zh) * | 2022-07-20 | 2024-03-29 | 西安近代化学研究所 | 一种还原胺化法合成杀菌剂乙嘧酚的方法 |
| WO2024049721A1 (fr) * | 2022-08-31 | 2024-03-07 | Merck Sharp & Dohme Llc | Administration à libération prolongée d'un inhibiteur de pde10 |
| WO2024099135A1 (fr) * | 2022-11-11 | 2024-05-16 | 杭州中美华东制药有限公司 | Inhibiteur de 1,5-naphtyridine cgas et son utilisation |
| CN120936353A (zh) * | 2023-03-29 | 2025-11-11 | 默沙东有限责任公司 | 控释pde10a制剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1755611A1 (fr) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique |
| CA2583654C (fr) | 2004-10-12 | 2015-02-17 | Maxlinear, Inc. | Architecture de recepteur a frequence intermediaire generee numeriquement |
| KR100896380B1 (ko) | 2005-01-07 | 2009-05-08 | 화이자 프로덕츠 인코포레이티드 | 헤테로방향족 퀴놀린 화합물 및 ｐｄｅ10 저해제로서의그의 용도 |
| GB0506883D0 (en) * | 2005-04-05 | 2005-05-11 | Astrazeneca Ab | Chemical compounds |
| JP2008534662A (ja) * | 2005-04-05 | 2008-08-28 | アストラゼネカ アクチボラグ | 抗癌剤として使用されるピリミジン誘導体 |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| US20090176829A1 (en) | 2006-05-02 | 2009-07-09 | Pfizer Inc | Bicyclic heteroaryl compounds as pde10 inhibitors |
| US20110230472A1 (en) * | 2008-08-29 | 2011-09-22 | Shionogi & Co., Ltd. | Ring-fused azole derivative having pi3k-inhibiting activity |
| MX2011002399A (es) | 2008-09-04 | 2011-04-07 | Mitsubishi Tanabe Pharma Corp | Compuestos pirimidina tri-sustituida y su uso como inhibidores de fosfodiesterasa 10. |
| EP2342191B1 (fr) | 2008-09-10 | 2013-03-20 | Mitsubishi Tanabe Pharma Corporation | Composés cycliques aromatiques azotés à 6 chaînons et leur utilisation |
| TW201030001A (en) * | 2008-11-14 | 2010-08-16 | Amgen Inc | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
| ES2397934T3 (es) * | 2008-12-17 | 2013-03-12 | Amgen Inc. | Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10 |
| WO2011008931A2 (fr) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Composés arylpyrimidines et thérapie de combinaison comprenant ceux-ci pour traiter une mucoviscidose et des troubles apparentés |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| US8470820B2 (en) * | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
| WO2012044561A2 (fr) * | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Inhibiteurs de 2-alcoxy pyrimidine pde10 |
| WO2012044562A2 (fr) * | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Inhibiteurs de pyrazolopyrimidine pde10 |
-
2012
- 2012-08-20 BR BR112014004310A patent/BR112014004310B8/pt active IP Right Grant
- 2012-08-20 TW TW101130166A patent/TWI450895B/zh active
- 2012-08-20 US US14/239,603 patent/US9062059B2/en active Active
- 2012-08-20 PH PH1/2014/500424A patent/PH12014500424A1/en unknown
- 2012-08-20 HU HUE12826375A patent/HUE028451T2/en unknown
- 2012-08-20 HR HRP20160635TT patent/HRP20160635T1/hr unknown
- 2012-08-20 MY MYPI2014000504A patent/MY157301A/en unknown
- 2012-08-20 SG SG2014013536A patent/SG2014013536A/en unknown
- 2012-08-20 DK DK12826375.3T patent/DK2748151T3/en active
- 2012-08-20 PE PE2014000255A patent/PE20141535A1/es active IP Right Grant
- 2012-08-20 EP EP12826375.3A patent/EP2748151B1/fr active Active
- 2012-08-20 KR KR1020147007427A patent/KR101655635B1/ko active Active
- 2012-08-20 SI SI201230539A patent/SI2748151T1/sl unknown
- 2012-08-20 CN CN201280052330.4A patent/CN103917528B/zh active Active
- 2012-08-20 UA UAA201403008A patent/UA109735C2/ru unknown
- 2012-08-20 MX MX2014002178A patent/MX357241B/es active IP Right Grant
- 2012-08-20 ES ES12826375.3T patent/ES2572527T3/es active Active
- 2012-08-20 WO PCT/US2012/051522 patent/WO2013028590A1/fr not_active Ceased
- 2012-08-20 EA EA201490492A patent/EA023685B1/ru not_active IP Right Cessation
- 2012-08-20 RS RS20160357A patent/RS54788B1/sr unknown
- 2012-08-20 AU AU2012299080A patent/AU2012299080B2/en active Active
- 2012-08-20 PL PL12826375.3T patent/PL2748151T3/pl unknown
- 2012-08-20 JP JP2014527214A patent/JP5648147B2/ja active Active
- 2012-08-20 ME MEP-2016-101A patent/ME02419B/fr unknown
- 2012-08-20 CA CA2845578A patent/CA2845578C/fr active Active
- 2012-08-22 AR ARP120103086A patent/AR087628A1/es active IP Right Grant
-
2014
- 2014-02-16 IL IL230997A patent/IL230997A/en active IP Right Grant
- 2014-02-18 TN TNP2014000070A patent/TN2014000070A1/en unknown
- 2014-02-19 ZA ZA2014/01272A patent/ZA201401272B/en unknown
- 2014-02-24 NI NI201400014A patent/NI201400014A/es unknown
- 2014-02-24 CR CR20140085A patent/CR20140085A/es unknown
- 2014-02-25 CL CL2014000450A patent/CL2014000450A1/es unknown
- 2014-02-25 DO DO2014000039A patent/DOP2014000039A/es unknown
- 2014-02-27 CO CO14042266A patent/CO6890101A2/es unknown
- 2014-03-13 MA MA6829A patent/MA35508B1/fr unknown
-
2016
- 2016-06-10 CY CY20161100512T patent/CY1117622T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35508B1 (fr) | Inhibiteurs pyrimidines de pde10 | |
| MX2017011935A (es) | Compuestos de triazolil pirimidinona como inhibidores de la enzima fosfodiesterasa 2 (pde2). | |
| WO2012044561A3 (fr) | Inhibiteurs de 2-alcoxy pyrimidine pde10 | |
| WO2012044562A3 (fr) | Inhibiteurs de pyrazolopyrimidine pde10 | |
| MA44656B1 (fr) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones et 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones en tant qu'inhibiteurs de pde1 | |
| EA201000314A1 (ru) | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны | |
| MA43756B1 (fr) | Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine | |
| CL2011002838A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos de receptores mglur2; composición farmacéutica; proceso para prepararla; y su uso en el tratamiento o la prevención de un trastorno del sistema nervioso central seleccionado de ansiedad y esquizofrenia, entre otros. | |
| EA201000332A1 (ru) | 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны | |
| MA32110B1 (fr) | Derives heterocycliques bicycliques pontes ou derives heterocyclique spiro-bicycliques de pyrazolo [1,5-a] pyrimidines, procedes pour leur preparation et leurs utilisations | |
| MX2019014597A (es) | Inhibidores de pirazolopirimidina de pde9. | |
| WO2012054366A3 (fr) | Amino-triazolyles inhibiteurs de ped10 | |
| EA201390710A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
| MX2020011489A (es) | Moduladores alostericos de espiropiperidina de receptores nicotinicos de acetilcolina. | |
| MA53351B1 (fr) | Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisations | |
| EA201990973A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| WO2014150114A8 (fr) | Dérivés de pyridizinone substitués en tant qu'inhibiteurs de pde10 | |
| JOP20230217A1 (ar) | عقاقير أولية لمركبات pde10 | |
| CA3156131A1 (fr) | Composes antagonistes du recepteur de la prostaglandine ep4 | |
| ECSP14013268A (es) | Inhibidores de pde10 de pirimidina | |
| MA44503B1 (fr) | Composés de pyrrolotriazine en tant qu'inhibiteurs de tam | |
| TH147865A (th) | สารยับยั้ง pde10 ประเภทไพริมิดีน | |
| EA201892113A1 (ru) | Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов |